Prove first: clinics want this, but cash, competition, and rollout risk are still unproven.
You have a real pain point and early paying users, so this is not a fake problem. But the business is not yet self-funding, the market is crowded, and your expansion plan adds compliance and language risk that a small team can easily underestimate. The right call is to test the hard assumptions before you spend more.
- Conviction
- 56 of 100, weighted across six lenses
- Evidence behind it
- 42 of 100. The shaded span shows how far the call could move.
- Assumptions tested
- 0 of 7. Test the next one
Why this call
- 1The customer pain is real. Doctors in independent clinics still waste time typing notes after visits, so you are selling time back to people who already feel the cost.
- 2The unit economics are not safe yet. You have $560,000 cash, $18,500 monthly revenue, and $65,500 monthly operating costs, so your current burn gives you limited runway before break-even.
- 3Competition is strong and the category is crowded. Enterprise brands, lower-priced scribes, and workflow-tied tools can all block you unless you become clearly better for local clinic workflows.
- 4Your next growth steps are not simple. India, Dubai, and Singapore each add language, licensing, or compliance work, and those frictions can slow a small team before the product has fully proven repeatable sales.
What would change it
- If clinics with 2 to 15 doctors close quickly without enterprise procurement, the call should move up.
- If Hindi and Tamil notes are accurate in real consultations, the product risk drops sharply.
- If you cut burn enough to extend runway well past 12 months, the financial risk drops.
- If CAC stays low after the first few dozen clinics, the business becomes much more believable.
Six lenses
Each lens answers one question and is scored from 0 to 5. Economics is calculated from your numbers; the others come from the analysis.
Is this a problem people already pay or struggle to solve?
This is a real pain. You are selling to clinics where doctors still spend hours typing after visits, and that is exactly the kind of work they already know is waste. The buyer is not buying a nice-to-have feature; they are buying back physician time and more patient capacity.
3 open questions
- How many of your 62 customers use it weekly versus only trying it
- Whether the time saved shows up in accepted notes, more visits, or less after-hours work
- Whether doctors in small clinics in India, UAE, and Singapore will pay enough to keep using it
Are there enough reachable buyers to build a business?
The market is large enough in India alone to support a real business, and the same pain exists in UAE and Singapore. But your reachable market is narrower than the broad healthcare software market because you only sell to independent clinics with 2 to 15 doctors and no hospital IT team, and those buyers are fragmented and slow.
3 open questions
- How many independent clinics in your target countries fit your exact buyer profile
- What share of clinics will buy an AI scribe instead of a generic dictation or EHR add-on
- Whether country-by-country rollout creates too much sales and compliance overhead
Is there a reason this wins against the alternatives?
You are in a crowded category with strong brands and cheap substitutes. Enterprise tools like Abridge and Nuance DAX are real competitors, but so are lower-priced scribes and workflow-tied tools that are easier for small clinics to adopt. Your only durable edge is if you become the easiest clinic-specific workflow for local languages, local regulation, and local integrations.
3 open questions
- Whether your product is materially better for Indian clinic workflows than cheaper general scribes
- Whether clinics care more about note quality, price, language, or EHR integration
- Whether you can defend against incumbent bundling by EHR vendors
Does the money work before the cash runs out?
The current economics are not yet self-funding. You have $560,000 cash, $18,500 monthly revenue, and $65,500 monthly operating costs, which means about $52,180 net burn and roughly 8.6 months of runway on cash in hand. The current plan says break-even is month 24, so you need either faster growth, lower spend, or outside funding to avoid running out before the business covers itself.
- Runway. Cash in hand lasts about 9 months.
- Gross margin. 72% of revenue is left after delivery costs.
- Customer value. A customer returns 4.7x what it costs to win them.
- Payback. Acquisition cost is earned back in about 9 months.
Held down: Cash in hand runs out in about 9 months, before the business covers its own costs.
3 open questions
- Whether the 9% monthly revenue growth rate is sustained without pushing CAC higher
- Whether churn stays near 2.4% as you scale beyond early adopters
- Whether the planned hires and funding are realistic given the current runway
Can this team ship and sell it from here?
You have paying customers, early product-market signals, and a clear near-term roadmap. But the next steps depend on doing several hard things at once: language expansion, compliance work in India, a Dubai launch with a licensed local partner, and later Singapore. That is manageable only if your product already works reliably in live clinics and your sales motion is repeatable.
3 open questions
- Whether your team can ship Hindi and Tamil without hurting accuracy
- Whether you can close more clinics at a CAC of $1,900 without longer sales cycles
- Whether the planned UAE and Singapore launches need more operational depth than your current team has
Could regulation, politics or geography block it?
Regulatory exposure is real and country-specific. In India, medical software can fall under medical device software rules and the CDSCO has issued guidance; in Singapore, software used in medical applications can be regulated by HSA; and in the UAE, healthcare licensing and local partner requirements can slow market entry. None of this looks like an automatic stop, but it can block launches if you treat compliance as a later task.
3 open questions
- Whether Quillwell is classified as medical device software in each market
- Whether your note generation, storage, or clinical decision support triggers extra requirements
- Whether the Dubai partner structure is enough for lawful market access and data handling
Three moves that would teach you the most
- Measure retention by cohort and workflow
This tells you whether customers stay because the product is essential or because they are still experimenting. It also shows whether newer customers behave better than early adopters.
A few days
- Test language quality on real consultations
Hindi and Tamil are a major planned expansion point. You need to know if the model is good enough before you spend on sales and distribution around it.
A few weeks
- Map the minimum compliance path for each country
This settles whether India, Dubai, and Singapore are launch markets or paperwork traps. It also tells you if the Dubai partner plan is viable.
A few weeks
Riskiest untested assumptions
- Clinics with 2 to 15 doctors can be sold without a long enterprise procurement cycle.
Test: Run 20 new outbound demos and measure time from first meeting to paid conversion.
- Hindi and Tamil dictation will be accurate enough to be useful in real consultations.
Test: Benchmark the feature on 50 real or recorded consultations in each language and compare edit time against English.
- Customer acquisition cost will stay low enough as you scale beyond early adopters.
Test: Track CAC by channel for the next 15 wins and compare to cohort retention after 60 days.